Strata Critical Medical(SRTA)
$6.01-0.01 (-0.17%)
SRTA
Strata Critical Medical financials statements
$6.01
At close:-0.01 (-0.17%)
Want to see SRTA full AI Analyst Report?
Strata Critical Medical (SRTA) Ratios
1,020 Followers
Strata Critical Medical Ratios
SRTA's free cash flow for Q3 2026 was $9.06M. For the 2026 fiscal year, SRTA's free cash flow was decreased by $-400.00K and operating cash flow was $9.46M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Sep 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.38 | 7.07 | 5.81 | 8.20 | 23.07 |
| Quick Ratio | 6.38 | 7.07 | 5.81 | 8.20 | 23.03 |
| Cash Ratio | 1.56 | 0.81 | 0.79 | 1.55 | 0.20 |
| Solvency Ratio | 1.04 | -0.61 | -0.81 | -0.86 | -0.89 |
| Operating Cash Flow Ratio | -2.47 | -0.11 | -0.91 | -1.40 | -1.22 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 79.79M | $ 126.00M | $ 145.62M | $ 167.59M | $ 250.43M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.04 | 0.08 | 0.06 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.04 | 0.10 | 0.07 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.04 | 0.09 | 0.06 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.17 | 1.16 | 1.26 | 1.18 | 1.15 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.12 | 0.33 | 0.26 | 0.01 |
| Net Debt to EBITDA | 4.85 | 0.42 | 0.05 | 0.33 | 0.08 |
| Profitability Margins | |||||
| Gross Profit Margin | 20.86% | 23.69% | 18.71% | 15.24% | 20.82% |
| EBIT Margin | -6.40% | -11.08% | -30.25% | -36.63% | -47.68% |
| EBITDA Margin | -2.90% | -8.69% | -27.09% | -47.81% | -46.50% |
| Operating Profit Margin | -11.34% | -13.64% | -30.25% | -36.63% | -47.68% |
| Pretax Profit Margin | -10.18% | -11.08% | -25.55% | -19.18% | -86.48% |
| Net Profit Margin | 20.97% | -10.98% | -24.90% | -18.66% | -79.27% |
| Continuous Operations Profit Margin | -10.18% | -10.98% | -24.90% | -18.66% | -79.27% |
| Net Income Per EBT | -206.06% | 99.07% | 97.45% | 97.25% | 91.66% |
| EBT Per EBIT | 89.77% | 81.24% | 84.48% | 52.37% | 181.36% |
| Return on Assets (ROA) | 12.70% | -10.64% | -19.01% | -8.39% | -11.92% |
| Return on Equity (ROE) | 14.82% | -12.30% | -23.93% | -9.93% | -13.75% |
| Return on Capital Employed (ROCE) | -7.31% | -14.50% | -26.25% | -17.94% | -7.46% |
| Return on Invested Capital (ROIC) | -7.30% | -14.17% | -25.12% | -17.25% | -6.83% |
| Return on Tangible Assets | 21.79% | -13.52% | -23.96% | -11.40% | -13.43% |
| Earnings Yield | 10.43% | -8.29% | -21.61% | -10.69% | -5.49% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.93 | 11.52 | 10.72 | 13.43 | 9.11 |
| Payables Turnover | 8.15 | 0.00 | 0.00 | 7.49 | 6.28 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 73.14 |
| Fixed Asset Turnover | 4.98 | 6.25 | 8.54 | 7.41 | 18.32 |
| Asset Turnover | 0.61 | 0.97 | 0.76 | 0.45 | 0.15 |
| Working Capital Turnover Ratio | 1.61 | 1.61 | 1.24 | 0.62 | 0.35 |
| Cash Conversion Cycle | 29.20 | 31.69 | 34.05 | -21.57 | -13.04 |
| Days of Sales Outstanding | 73.98 | 31.69 | 34.05 | 27.17 | 40.08 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 4.99 |
| Days of Payables Outstanding | 44.78 | 0.00 | 0.00 | 48.74 | 58.11 |
| Operating Cycle | 73.98 | 31.69 | 34.05 | 27.17 | 45.07 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.59 | -0.03 | -0.44 | -0.52 | -0.22 |
| Free Cash Flow Per Share | -0.73 | -0.46 | -0.47 | -0.53 | -0.23 |
| Dividend Paid and CapEx Coverage Ratio | -4.44 | -0.08 | -15.34 | -50.86 | -19.49 |
| Capital Expenditure Coverage Ratio | -4.44 | -0.08 | -15.34 | -50.86 | -19.49 |
| Operating Cash Flow Coverage Ratio | -14.79 | -0.27 | -1.32 | -2.03 | -21.81 |
| Operating Cash Flow to Sales Ratio | -0.25 | -0.01 | -0.14 | -0.25 | -0.31 |
| Free Cash Flow Yield | -15.11% | -10.78% | -13.28% | -14.85% | -2.25% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 9.62 | -12.14 | -4.63 | -9.36 | -18.20 |
| Price-to-Sales (P/S) Ratio | 2.01 | 1.32 | 1.15 | 1.75 | 14.43 |
| Price-to-Book (P/B) Ratio | 1.42 | 1.48 | 1.11 | 0.93 | 2.50 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.62 | -9.27 | -7.53 | -6.74 | -44.41 |
| Price-to-Operating Cash Flow Ratio | -8.11 | -130.76 | -8.02 | -6.87 | -46.69 |
| Price-to-Earnings Growth (PEG) Ratio | -0.04 | 0.23 | -0.05 | 0.28 | 0.61 |
| Enterprise Value Multiple | -64.63 | -14.83 | -4.20 | -3.32 | -30.95 |
| Enterprise Value | 368.95M | 320.32M | 256.19M | 232.03M | 727.12M |
| EV to EBITDA | -64.63 | -14.83 | -4.20 | -3.32 | -30.95 |
| EV to Sales | 1.87 | 1.29 | 1.14 | 1.59 | 14.39 |
| EV to Free Cash Flow | -6.16 | -9.02 | -7.43 | -6.13 | -44.29 |
| EV to Operating Cash Flow | -7.54 | -127.16 | -7.92 | -6.25 | -46.57 |
| Tangible Book Value Per Share | 1.74 | 2.16 | 2.36 | 2.65 | 3.62 |
| Shareholders’ Equity Per Share | 3.38 | 2.86 | 3.19 | 3.85 | 4.16 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.01 | 0.03 | 0.03 | 0.08 |
| Revenue Per Share | 2.39 | 3.21 | 3.06 | 2.05 | 0.72 |
| Net Income Per Share | 0.50 | -0.35 | -0.76 | -0.38 | -0.57 |
| Tax Burden | -2.06 | 0.99 | 0.97 | 0.97 | 0.92 |
| Interest Burden | 1.59 | 1.00 | 0.84 | 0.52 | 1.81 |
| Research & Development to Revenue | 0.02 | 0.01 | 0.02 | 0.04 | 0.03 |
| SG&A to Revenue | 0.31 | 0.36 | 0.42 | 0.43 | 0.60 |
| Stock-Based Compensation to Revenue | 0.09 | 0.08 | 0.06 | 0.06 | 0.19 |
| Income Quality | -1.18 | 0.09 | 0.58 | 1.36 | 0.39 |
Currency in USD
